AMETEK, Inc. reports developments as a global industrial technology company serving niche markets through Electronic Instruments and Electromechanical operations. Its news commonly covers operating results, segment trends, dividend actions, board governance and strategic acquisitions tied to analytical, test and measurement instruments, highly engineered components, interconnects, specialty metals and medical technology products.
Company updates also describe AMETEK's capital deployment approach, including acquisitions that expand product portfolios such as ophthalmic diagnostic devices, and recurring financial commentary on sales, margins, cash generation and earnings guidance.
AMETEK (NYSE: AME) appointed Nick L. Stanage to its Board of Directors effective May 8, 2026.
Stanage is former chairman and CEO of Hexcel (NYSE: HXL), retired May 2024, and currently serves on the boards of Hexcel, Huntington Ingalls Industries, and TriMas. AMETEK reports ~$7.5 billion in annual sales.
AMETEK (NYSE: AME) declared a regular quarterly dividend of $0.34 per share for the quarter ending June 30, 2026. The dividend is payable on June 30, 2026 to shareholders of record as of June 15, 2026.
AMETEK reports approximately $7.5 billion in annual sales and reiterates its Growth Model focused on operational excellence, technology innovation, global expansion, and strategic acquisitions.
AMETEK (NYSE: AME) agreed to acquire Indicor Instrumentation in an all-cash transaction valued at approximately $5.0 billion, expected to close in the second half of 2026 subject to regulatory approvals.
Indicor generates about $1.1 billion in annual sales and will be integrated into AMETEK's Electronic Instruments Group and Electromechanical Group. AMETEK plans to fund the deal with borrowings under its credit facility and new debt issuance.
AMETEK (NYSE: AME) announced an agreement to acquire First Aviation Services, a defense and aviation MRO provider with annual sales of approximately $80 million and six U.S. centers of excellence. The deal expands AMETEK's component MRO capabilities across electronics, rotor blades, propellers, landing gear and flight controls. The transaction is subject to customary closing conditions, including regulatory approvals.
AMETEK reported annual sales of about $7.5 billion and reiterated its Growth Model focused on operational excellence, technology innovation, global expansion and strategic acquisitions.
AMETEK (NYSE: AME) reported record Q1 2026 results: sales $1.93 billion (+11% YoY), GAAP EPS $1.74, and adjusted EPS $1.97 (+13% YoY). GAAP operating income was $514.9 million; adjusted operating income was $516.6 million and margins rose to 26.8% (+50 bps). Orders grew 23%, producing a record backlog. Management raised 2026 adjusted EPS guidance to $7.94–$8.14 and expects full-year sales up high single digits. AMETEK highlighted strong organic growth, acquisition contributions, and cash-generative operations.
AMETEK (NYSE: AME) will release first quarter 2026 earnings before the market opens on Thursday, April 30, 2026 and will host a live investor conference call the same day at 8:30 AM ET. The live audio webcast and replay will be available via the Investors > Events & Presentations section of www.ametek.com.
Corporate profile: AMETEK reported annual sales of approximately $7.5 billion, aims for double‑digit EPS growth over the business cycle, pursues four growth strategies, and is a component of the S&P 500.
AMETEK (NYSE: AME) announced a 10% increase in its quarterly cash dividend to $0.34 per share from $0.31. The first-quarter dividend is payable March 31, 2026 to holders of record on March 16, 2026, raising the indicated annual rate to $1.36 per share.
Management cited strong growth, cash flow generation and a solid financial position, and reaffirmed a commitment to strategic acquisitions alongside returning cash to shareholders. Company annual sales are about $7.5 billion.
DW Healthcare Partners announced the sale of LKC Technologies to AMETEK (NYSE: AME) on Feb. 3, 2026. LKC, a portfolio company of DWHP's Founders Fund, develops the handheld, non-invasive RETeval electroretinography (ERG) device to support retinal and optic nerve disease diagnosis. William Blair was exclusive financial advisor to LKC.
The announcement highlights LKC's 35+ years of diagnostic innovation and DWHP's three-year partnership to scale operations and raise awareness of functional retinal testing.
AMETEK (NYSE: AME) announced on February 3, 2026 the acquisition of LKC Technologies, a provider of portable diagnostic devices for ophthalmic conditions, joining AMETEK's Electronic Instruments Group (EIG).
The deal expands AMETEK's ophthalmic product portfolio, aligns LKC with the Ultra Precision Technologies Reichert business, and supports market expansion in eye‑care diagnostics. AMETEK reported annual sales of approximately $7.5 billion and reaffirmed its growth model emphasizing strategic acquisitions and double‑digit EPS growth over the cycle.
AMETEK (NYSE: AME) reported record fourth-quarter and full‑year 2025 results on Feb 3, 2026. Q4 sales were $2.0 billion, +13% YoY, GAAP EPS was $1.73 and adjusted EPS was a record $2.01. Q4 adjusted operating income was $523.0 million.
For full year 2025, sales were $7.4 billion (+7% YoY), GAAP EPS $6.40, adjusted EPS $7.43 (+9% YoY). Free cash flow and several operating metrics set annual records. 2026 guidance: sales up mid‑to‑high single digits; adjusted EPS $7.87–$8.07.